146 related articles for article (PubMed ID: 21426886)
1. Education for dialysis patients lowers long-term phosphate levels and maintains health-related quality of life.
Gardulf A; Pålsson M; Nicolay U;
Clin Nephrol; 2011 Apr; 75(4):319-27. PubMed ID: 21426886
[TBL] [Abstract][Full Text] [Related]
2. Dietitian-led education program to improve phosphate control in a single-center hemodialysis population.
Reddy V; Symes F; Sethi N; Scally AJ; Scott J; Mumtaz R; Stoves J
J Ren Nutr; 2009 Jul; 19(4):314-20. PubMed ID: 19539185
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).
Biggar P; Ketteler M
Expert Opin Pharmacother; 2010 Nov; 11(16):2739-50. PubMed ID: 20977406
[TBL] [Abstract][Full Text] [Related]
4. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
5. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
6. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
7. The treatment of hyperphosphataemia in CKD: calcium-based or calcium-free phosphate binders?
Cozzolino M; Mazzaferro S; Brandenburg V
Nephrol Dial Transplant; 2011 Feb; 26(2):402-7. PubMed ID: 21079194
[No Abstract] [Full Text] [Related]
8. Early initiation of phosphate lowering dietary therapy in non-dialysis chronic kidney disease: a critical review.
Sigrist MK; Chiarelli G; Lim L; Levin A
J Ren Care; 2009 Mar; 35 Suppl 1():71-8. PubMed ID: 19222735
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of educational interventions with dialysis patient].
Parmier M; Gourieux B; Krummel T; Bazin-Kara D; Dory A; Hannedouche T
Nephrol Ther; 2016 Dec; 12(7):516-524. PubMed ID: 27776970
[TBL] [Abstract][Full Text] [Related]
10. Effect of intensified diet education on serum phosphorus and knowledge of pediatric peritoneal dialysis patients.
Abercrombie EL; Greenbaum LA; Baxter DH; Hopkins B
J Ren Nutr; 2010 May; 20(3):193-8. PubMed ID: 20303791
[TBL] [Abstract][Full Text] [Related]
11. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
12. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
[TBL] [Abstract][Full Text] [Related]
13. Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice.
Toussaint ND; Pedagogos E; Beavis J; Becker GJ; Polkinghorne KR; Kerr PG
Nephrol Dial Transplant; 2011 Apr; 26(4):1319-26. PubMed ID: 20935019
[TBL] [Abstract][Full Text] [Related]
14. The impact of nurse-led education on haemodialysis patients' phosphate binder medication adherence.
Sandlin K; Bennett PN; Ockerby C; Corradini AM
J Ren Care; 2013 Mar; 39(1):12-8. PubMed ID: 23432740
[TBL] [Abstract][Full Text] [Related]
15. Patients' satisfaction with information about phosphate-binding medication.
Parham R; Riley S; Hutchinson A; Horne R
J Ren Care; 2009 Mar; 35 Suppl 1():86-93. PubMed ID: 19222738
[TBL] [Abstract][Full Text] [Related]
16. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial.
Shahbazian H; Zafar Mohtashami A; Ghorbani A; Abbaspour MR; Belladi Musavi SS; Hayati F; Lashkarara GR
Nefrologia; 2011; 31(1):58-65. PubMed ID: 21270914
[TBL] [Abstract][Full Text] [Related]
17. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
18. [Should we consider the cost-effectiveness analysis to apply the recommendations for phosphate-binders administration?].
Martín de Francisco AL
Nefrologia; 2008; 28(2):129-34. PubMed ID: 18454700
[No Abstract] [Full Text] [Related]
19. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
20. Adherence to phosphate binders in hemodialysis patients: prevalence and determinants.
Van Camp YP; Vrijens B; Abraham I; Van Rompaey B; Elseviers MM
J Nephrol; 2014 Dec; 27(6):673-9. PubMed ID: 24563270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
